Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024325 | 0.85 | PSEN1 (0.42) | PTPN1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4953627 | 0.82 | PTPN1 (0.46) | PTPN1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4023946 | 0.82 | ALDH1A1 (0.41) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4021086 | 0.80 | PTPN1 (0.37) | PTPN1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6582980 | 0.80 | PTPN1 (0.66) | PTPN1PRNPRXFP1ALDH1A1 | |
| SCHEMBL4027205 | 0.78 | PTPN1 (0.41) | PTPN1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4026345 | 0.75 | PSEN1 (0.41) | PTPN1PPARGPSEN1PSEN2APH1B | |
| SCHEMBL5345667 | 0.75 | ALDH1A1 (0.41) | TP53ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4026179 | 0.74 | PTPN1 (0.38) | PTPN1PRNPRXFP1ALDH1A1HPGD | |
| SCHEMBL3853394 | 0.73 | PPARG (0.67) | PTPN1PPARGPPARAPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | claimed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | claimed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | claimed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | claimed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | claimed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | claimed |
| EP-1397356-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | claimed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | claimed |
| WO-2003000684-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070185186-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-08-09 | — | — | US | disclosed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | disclosed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | disclosed |
| EP-1397356-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2003000684-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185186-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | INMT, AANAT, NAPEPLD | PTPN1 3234/4885PPARG 1685/4885PPARA 1208/4885 |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | TFPI, SERPINE1, F12 | PTPN1 658/4885PPARG 606/4885PPARA 787/4885 |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PTPN1 958/4885PPARG 357/4885PPARA 433/4885 |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PTPN1 902/4885PPARG 349/4885PPARA 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.